ALL SESSIONS

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immuno-therapies

Antibody Drug Conjugates

Antibody-Drug Conjugates

Industry Sponsored

View Sessions

Alessandra Curioni Fontecedro on PD-L1 negative NSCLC
May 04 2026
SPONSORED INTERVIEW

APPROACHES IN METASTATIC PD-L1 NEGATIVE NSCLC

} 14 min

Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
METASTATIC NSCLC, SCLC

2025 Approvals & Highlights

} 1 h 49 min

Sep 26 2025
INDUSTRY SYMPOSIUM

UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC

} 30 min

Sep 26 2025
SCLC

RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE

} 34 min

Sep 26 2025
METASTATIC NSCLC

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

} 32 min

Sep 26 2025
IMMUNOTHERAPIES

THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC

} 28 min

Sep 26 2025
IMMUNOTHERAPIES

TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES

} 36 min

Sep 26 2025
SPONSORED INTERVIEW

Latest Advances in Frontline EGFR+ NSCLC

} 14 min

Sep 26 2025
ADCs

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

} 27 min

Sep 26 2025
TARGETED THERAPIES

DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

} 31 min

Sep 26 2025
TARGETED THERAPIES

ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET

} 26 min

Sep 26 2025
TARGETED THERAPIES

TARGETING EGFR AND ALK IN NSCLC

} 26 min

Sep 26 2025
BIOMARKERS

CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

} 24 min

Sep 26 2025
METASTATIC NSCLC

Open Discussion on Patient Cases

} 22 min

Targeted Therapies by Oliver Gautschi, Jarushka Naidoo, Nicolas Girard
Jul 10 2025
TARGETED THERAPIES

Targeted Therapies in NSCLC

} 1h 30 min

ILCS 2026

International Lung Cancer Summit 2026

ADD THIS TO YOUR CALENDAR

Following the success of the previous International Lung Cancer Summits (ILCS), we warmly invite you to the 8th edition, expertly chaired by the distinguished duo Solange Peters and Alfredo Addeo. This premier hybrid conference continues its tradition of excellence by highlighting the latest breakthroughs in lung cancer treatment. With a global lineup of renowned speakers from the USA, Japan, France, Portugal, Italy, Ireland, Greece, and the Netherlands, the ILCS provides a unique platform for professionals from clinics, universities, and research institutes to engage, network, and collaborate. By leveraging digital platforms, the summit fosters a dynamic environment for sharing insights and advancing lung cancer care.

CHUV-HUG Logo
ISREC
IASLC
ETOP
OncoViews

LED BY GLOBAL EXPERTS

Umberto Malapelle

Italy

Hidehito Horinouchi

Japan

Telma Sequeira

Portugal

Christine Lovly

USA

David Planchard

France

Sandip Patel

USA

Jarushka Naidoo

Ireland

Giannis Mountzios

Greece

Anne-Marie Dingemans

Netherlands

ADD THIS TO YOUR CALENDAR

Indication Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Metastatic Lung Cancer

Metastatic NSCLC

Lung Cancer

SCLC

Biomarkers

Biomarkers & Diagnostics

DRUG CLASSES

Pill

Targeted Therapies

OncoNews

Immunotherapies

Antibody Drug Conjugates

Antibody-Drug Conjugates